Dose Ranging Study With the Probiotic Combination (VSL#3) in Diarrhea IBS
Not Applicable
Terminated
- Conditions
- IBS
- Registration Number
- NCT00179582
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Brief Summary
To evaluate the effects of VSL#3 on symptoms associated with diarrhea predominant IBS
- Detailed Description
The study will evaluate 2 doses of VSL#3 and placebo over a 4 week period in patients presenting with diarrhea predominant IBS symptoms.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 180
Inclusion Criteria
- IBS diarrhea
Exclusion Criteria
- < 18 years of age
- Pregnancy/breast feeding
- concomitant medications to reduce bowel function
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Global improvement in IBS symptoms
- Secondary Outcome Measures
Name Time Method Frequency of bowel movements Changes in bloating Changes in abdominal pain
Trial Locations
- Locations (1)
BIDMC
🇺🇸Boston, Massachusetts, United States
BIDMC🇺🇸Boston, Massachusetts, United States